RT Book, Section A1 Williams, Felicia N. A1 Rodeberg, David A. A2 Ziegler, Moritz M. A2 Azizkhan, Richard G. A2 Allmen, Daniel von A2 Weber, Thomas R. SR Print(0) ID 1100439380 T1 Diagnosis and Treatment of Rhabdomyosarcoma T2 Operative Pediatric Surgery, 2e YR 2014 FD 2014 PB McGraw-Hill Education PP New York, NY SN 978-0-07-162723-8 LK accesssurgery.mhmedical.com/content.aspx?aid=1100439380 RD 2024/03/29 AB Overall 5-year survival for rhabdomyosarcoma has increased from 25% to 70% over the past 50 years.Embryonal rhabdomyosacrcoma (ERMS) occurs in younger children and has a more favorable survival rate of 60%.In patients with alveolar tumors (ARMS), the presence of regional nodes disease indicates a significantly worse prognosis, similar to metastatic disease, whereas in ERMS tumors the outcomes for patients with regional node disease is not any different than localized disease.All patients with RMS receive some form of chemotherapy. Standard therapeutic regimens consist of a combination of vincristine, actinomycin-D, and cyclophosphamide (VAC).Radiotherapy (RT) is an important adjunct to therapy for many children diagnosed with RMS, offering improved local control and outcomes.A more aggressive surgical approach may be warranted for recurrent RMS and debulking is indicated in retroperitoneal tumors.